Your browser doesn't support javascript.
loading
Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors.
Vasbinder, Alexi; Hoeger, Christopher W; Catalan, Tonimarie; Anderson, Elizabeth; Chu, Catherine; Kotzin, Megan; Xie, Jeffrey; Kaakati, Rayan; Berlin, Hanna P; Shadid, Husam; Perry, Daniel; Pan, Michael; Takiar, Radhika; Padalia, Kishan; Mills, Jamie; Meloche, Chelsea; Bardwell, Alina; Rochlen, Matthew; Blakely, Pennelope; Leja, Monika; Banerjee, Mousumi; Riwes, Mary; Magenau, John; Anand, Sarah; Ghosh, Monalisa; Pawarode, Attaphol; Yanik, Gregory; Nathan, Sunita; Maciejewski, John; Okwuosa, Tochukwu; Hayek, Salim S.
Afiliación
  • Vasbinder A; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Hoeger CW; Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Catalan T; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Anderson E; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Chu C; Rush Medical College, Rush University, Chicago, Illinois, USA.
  • Kotzin M; Rush Medical College, Rush University, Chicago, Illinois, USA.
  • Xie J; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Kaakati R; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Berlin HP; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Shadid H; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Perry D; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Pan M; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Takiar R; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Padalia K; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Mills J; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Meloche C; Division of Cardiovascular Medicine, Texas Heart Institute, Houston, Texas, USA.
  • Bardwell A; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Rochlen M; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Blakely P; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Leja M; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Banerjee M; Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
  • Riwes M; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Magenau J; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Anand S; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Ghosh M; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Pawarode A; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Yanik G; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Nathan S; Division of Hematology, Oncology and Cell Therapy, Department of Internal Medicine, Rush Medical College, Chicago, Illinois, USA.
  • Maciejewski J; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Okwuosa T; Division of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Hayek SS; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
JACC CardioOncol ; 5(6): 821-832, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38205002
ABSTRACT

Background:

Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications.

Objectives:

We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients.

Methods:

We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT).

Results:

In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events.

Conclusions:

The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: JACC CardioOncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: JACC CardioOncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos